Rani Isha, Kaur Navgeet, Goyal Anju, Sharma Manish
Chitkara College of Pharmacy, Chitkara University, Punjab, India.
M.M. College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala-133207, Haryana, India.
Anticancer Agents Med Chem. 2023;23(5):525-561. doi: 10.2174/1871520622666220701113204.
Heterocyclic compounds are recognized to possess a high grade of structural diversity and a broad spectrum of therapeutic properties. About two-thirds of the New Chemical Entities approved by the FDA against cancer entail heterocyclic rings and are the foundation stone of medicinal chemistry. Pyrimidine being a major heterocyclic compound and a crucial base component of the genetic material, has emerged as the key structural component against cancer, the deadliest disease worldwide. Though many drugs are marketed against cancer, researchers are still investigating the more promising moieties against various malignancies due to the severity of this disease. In this review, an attempt has been made to assemble the reported literature of the previous five years on various synthetic procedures and the anti-cancer potential of various classes of fused pyrimidine analogs, which would help the researchers in designing new potent derivatives. Besides this, the review intends to focus on the comprehensive discussion on biological targets, modes of action, and structure-activity relationships of each class of fused pyrimidines as potential anticancer agents.
杂环化合物具有高度的结构多样性和广泛的治疗特性。美国食品药品监督管理局（FDA）批准的用于抗癌的新化学实体中，约三分之二含有杂环，是药物化学的基石。嘧啶作为一种主要的杂环化合物和遗传物质的关键碱基成分，已成为对抗全球最致命疾病——癌症的关键结构成分。尽管有许多抗癌药物已上市，但由于这种疾病的严重性，研究人员仍在研究针对各种恶性肿瘤更有前景的部分。在本综述中，我们试图收集过去五年中关于各种合成方法以及各类稠合嘧啶类似物抗癌潜力的报道文献，这将有助于研究人员设计新的强效衍生物。除此之外，本综述旨在重点全面讨论各类稠合嘧啶作为潜在抗癌剂的生物学靶点、作用方式和构效关系。
